Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically effective: Were monoclonal antibodies against COVID-19 rejected too early?
Line Lundegaard Bang, Lone Wulff Madsen, Rune Micha Pedersen, Anna Christine Nilsson, Isik Somuncu Johansen, Thomas Emil Andersen
Journal of Infection and Public Health, doi:10.1016/j.jiph.2024.102512
We read with interest the article by Behzad et al. [1
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Behzad, Ali, Niinuma, Butler, Alqahtani, Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2, J Infect Public Health
Cai, Diallo, Rosenthal, Ren, Flores et al., AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults, Sci Transl Med
Driouich, Bernadin, Touret, Lamballerie, Nougairède, Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model, Antivir Res
Drysdale, Gibbons, Singh, Rolland, Lavoie et al., Realworld effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review, Infection
Hérate, Touret, Dereuddre-Bosquet, Donati, Relouzat, Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a nonhuman primate model, Heliyon
Stadler, Burgess, Schlub, Khan, Chai et al., Monoclonal antibody levels and protection from COVID-19, Nat Commun
Supernova Phase, trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population
Uraki, Kiso, Iida, Imai, Takashita et al., Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2, Nature
Wilhelm, Widera, Grikscheit, Toptan, Schenk et al., Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies, eBioMedicine
Zhang, Stacey, Agostino, Tugg, Marzok et al., Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection, Nat Rev Immunol
{ 'indexed': {'date-parts': [[2024, 8, 13]], 'date-time': '2024-08-13T04:40:05Z', 'timestamp': 1723524005614},
'reference-count': 12,
'publisher': 'Elsevier BV',
'issue': '9',
'license': [ { 'start': { 'date-parts': [[2024, 9, 1]],
'date-time': '2024-09-01T00:00:00Z',
'timestamp': 1725148800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2024, 9, 1]],
'date-time': '2024-09-01T00:00:00Z',
'timestamp': 1725148800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/legal/tdmrep-license'},
{ 'start': { 'date-parts': [[2024, 7, 31]],
'date-time': '2024-07-31T00:00:00Z',
'timestamp': 1722384000000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by/4.0/'}],
'funder': [ { 'DOI': '10.13039/501100024075',
'name': 'Region of Southern Denmark',
'doi-asserted-by': 'publisher'}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.es', 'clinicalkey.com.au',
'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 9]]},
'DOI': '10.1016/j.jiph.2024.102512',
'type': 'journal-article',
'created': {'date-parts': [[2024, 8, 7]], 'date-time': '2024-08-07T02:24:28Z', 'timestamp': 1722997468000},
'page': '102512',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but remained clinically '
'effective: Were monoclonal antibodies against COVID-19 rejected too early?',
'prefix': '10.1016',
'volume': '17',
'author': [ {'given': 'Line Lundegaard', 'family': 'Bang', 'sequence': 'first', 'affiliation': []},
{'given': 'Lone Wulff', 'family': 'Madsen', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rune Micha', 'family': 'Pedersen', 'sequence': 'additional', 'affiliation': []},
{'given': 'Anna Christine', 'family': 'Nilsson', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-2189-9823',
'authenticated-orcid': False,
'given': 'Isik Somuncu',
'family': 'Johansen',
'sequence': 'additional',
'affiliation': []},
{'given': 'Thomas Emil', 'family': 'Andersen', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'issue': '2',
'key': '10.1016/j.jiph.2024.102512_bib1',
'doi-asserted-by': 'crossref',
'first-page': '315',
'DOI': '10.1016/j.jiph.2023.11.029',
'article-title': 'Real world effectiveness of sotrovimab in preventing COVID-19–related '
'hospitalisation or death in patients infected with Omicron BA.2',
'volume': '17',
'author': 'Behzad',
'year': '2024',
'journal-title': 'J Infect Public Health'},
{ 'issue': '1',
'key': '10.1016/j.jiph.2024.102512_bib2',
'doi-asserted-by': 'crossref',
'first-page': '1',
'DOI': '10.1007/s15010-023-02098-5',
'article-title': 'Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 '
'infection during Omicron BA.2 subvariant predominance: a systematic '
'literature review',
'volume': '52',
'author': 'Drysdale',
'year': '2024',
'journal-title': 'Infection'},
{ 'key': '10.1016/j.jiph.2024.102512_bib3',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ebiom.2022.104158',
'article-title': 'Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and '
'BA.2 by convalescent and vaccine serum and monoclonal antibodies',
'volume': '82',
'author': 'Wilhelm',
'year': '2022',
'journal-title': 'eBioMedicine'},
{ 'issue': '7917',
'key': '10.1016/j.jiph.2024.102512_bib4',
'doi-asserted-by': 'crossref',
'first-page': '119',
'DOI': '10.1038/s41586-022-04856-1',
'article-title': 'Characterization and antiviral susceptibility of SARS-CoV-2 Omicron '
'BA.2',
'volume': '607',
'author': 'Uraki',
'year': '2022',
'journal-title': 'Nature'},
{ 'issue': '6',
'key': '10.1016/j.jiph.2024.102512_bib5',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.heliyon.2023.e16664',
'article-title': 'Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 '
'in a non-human primate model',
'volume': '9',
'author': 'Hérate',
'year': '2023',
'journal-title': 'Heliyon'},
{ 'key': '10.1016/j.jiph.2024.102512_bib6',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.antiviral.2023.105638',
'article-title': 'Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in '
'a hamster model',
'volume': '215',
'author': 'Driouich',
'year': '2023',
'journal-title': 'Antivir Res'},
{ 'key': '10.1016/j.jiph.2024.102512_bib7',
'unstructured': 'Zhang A, Stacey HD, D’Agostino MR, Tugg Y, Marzok A, Miller MS. Beyond '
'neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 '
'infection. Nat Rev Immunol; 2022 [Internet] [cited 2023 Sep 13]; '
'Available from: 〈https://www.nature.com/articles/s41577-022-00813-1〉.'},
{ 'key': '10.1016/j.jiph.2024.102512_bib8',
'unstructured': 'Therapeutics and COVID-19: living guideline, 16 September 2022. Geneva: '
'World Health Organization; 2022 (WHO/2019-nCoV/therapeutics/2022.5). '
'Available from: '
'https://iris.who.int/bitstream/handle/10665/362843/WHO-2019-nCoV-therapeutics-2022.5-eng.pdf.'},
{ 'issue': '1',
'key': '10.1016/j.jiph.2024.102512_bib9',
'doi-asserted-by': 'crossref',
'first-page': '4545',
'DOI': '10.1038/s41467-023-40204-1',
'article-title': 'Monoclonal antibody levels and protection from COVID-19',
'volume': '14',
'author': 'Stadler',
'year': '2023',
'journal-title': 'Nat Commun'},
{ 'issue': '753',
'key': '10.1016/j.jiph.2024.102512_bib10',
'doi-asserted-by': 'crossref',
'DOI': '10.1126/scitranslmed.ado2817',
'article-title': 'AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and '
'is protective in hamsters and well tolerated in adults',
'volume': '16',
'author': 'Cai',
'year': '2024',
'journal-title': 'Sci Transl Med'},
{ 'key': '10.1016/j.jiph.2024.102512_bib11',
'unstructured': 'SUPERNOVA Phase I.I.I. trial of sipavibart long-acting antibody met '
'primary endpoints in preventing COVID-19 in immunocompromised patient '
'population [Internet]. 2024 [cited 2024 Jul 8]. Available from: '
'〈https://www.astrazeneca.com/media-centre/press-releases/2024/supernova-trial-met-covid-19-prevention-endpoint.html〉.'},
{ 'key': '10.1016/j.jiph.2024.102512_bib12',
'unstructured': 'F.D.A. (Food and Drug Administration). Fact sheet for patients, parents, '
'and caregivers Emergency Use Authorization (EUA) of PEMGARDA '
'(pemivibart) for coronavirus disease 2019 (COVID-19) [Internet]. [cited '
'2024 Jul 15]. Available from: '
'〈https://www.fda.gov/media/177069/download〉.'}],
'container-title': 'Journal of Infection and Public Health',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1876034124002466?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S1876034124002466?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2024, 8, 12]],
'date-time': '2024-08-12T19:33:58Z',
'timestamp': 1723491238000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1876034124002466'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 9]]},
'references-count': 12,
'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2024, 9]]}},
'alternative-id': ['S1876034124002466'],
'URL': 'http://dx.doi.org/10.1016/j.jiph.2024.102512',
'relation': {},
'ISSN': ['1876-0341'],
'subject': [],
'container-title-short': 'Journal of Infection and Public Health',
'published': {'date-parts': [[2024, 9]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Sotrovimab lost neutralization efficacy against SARS-CoV-2 subvariants but '
'remained clinically effective: Were monoclonal antibodies against COVID-19 '
'rejected too early?',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'Journal of Infection and Public Health',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.jiph.2024.102512',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2024 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin '
'Abdulaziz University for Health Sciences.',
'name': 'copyright',
'label': 'Copyright'}],
'article-number': '102512'}
